Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ozempic (semaglutide)
Marketing
GLP-1s oust oncology as top late-stage pipeline value driver
For the first time in its 16-year pharma industry analysis, Deloitte found obesity drugs are the largest contributor to late-stage pipeline value.
Ben Adams
May 4, 2026 7:00am
Rybelsus brand retired in US as ‘Ozempic pill’ takes the stage
May 1, 2026 8:00am
Novo eyes adolescent diabetes approval for oral semaglutide
Apr 23, 2026 11:03am
Generic versions of Novo's semaglutide launch today in India
Mar 20, 2026 11:27am
Novo's US headquarters hit with FDA warning letter
Mar 10, 2026 11:40am
Novo and Hims & Hers team up to sell branded GLP-1s, ending feud
Mar 9, 2026 11:55am
